Table 2.
IPMA results with pooled sera raised in guinea pigs.
| Guinea pig groups (n = 6) |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 1, 3, 7, 8 | 2, 4, 5, 6, 9 | Control | |
| AHSV 1 | +++ | +++ | ||||||||||
| AHSV 2 | +++ | +++ | ||||||||||
| AHSV 3 | +++ | +++ | ||||||||||
| AHSV 4 | +++ | +++ | ++ | |||||||||
| AHSV 5 | ++ | +++ | +++ | ++ | +++ | |||||||
| AHSV 6 | +++ | +++ | ||||||||||
| AHSV 7 | ++ | +++ | +++ | |||||||||
| AHSV 8 | ++ | +++ | ++ | ++ | ++ | |||||||
| AHSV 9 | ++ | +++ | + | |||||||||
Single VP2 proteins (1–9) or with cocktails of 4 or 5 different VP2 proteins (1, 3, 7, 8 or 2, 4, 5, 6, 9, respectively) were used to immunize six guinea pigs per group. BSR monolayers were infected with each of the AHSV serotypes (AHSV1–AHSV9), and immunostained by binding of guinea pig antibodies followed by binding of conjugated α-guinea pigs rabbit serum. Staining was semi-quantitated by +++, ++, + for strong, medium, and weak staining, respectively.